Status note Described as Phase 3-ready; no Phase 3 initiated per filing, so stage is kept at Phase 2.
SLN312
Phase 1 · ActiveModality: siRNA
Aliases AZD1705
Target ANGPTL3
Partnerships AstraZeneca (collaboration; AZ will not pursue beyond Phase 1, Silence regains full global rights)
Indications
dyslipidemia(Phase 1)
Status note Phase 1 results presented May 2026; Silence evaluating plans for further clinical development; no discontinuation disclosed.
SLN365
Preclinical · ActiveModality: siRNA
Target GPR146
Indications
hypercholesterolemia(Preclinical)
Catalysts
— 2027
Status note Preclinical; well positioned for a potential IND filing in 2027.
SLN098
Preclinical · ActiveModality: siRNA
Target INHBE
Indications
obesity(Preclinical)
Status note Preclinical.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.